Hemostasis Today

May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Anand Padmanabhan: Persistence and Pathogenicity of Platelet Factor 4 Antibodies in VITT
Apr 7, 2026, 19:17

Anand Padmanabhan: Persistence and Pathogenicity of Platelet Factor 4 Antibodies in VITT

Anand Padmanabhan, Professor and Clinician-Investigator at Mayo Clinic, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:

“We are pleased to publish this paper on VITT as part of a multi-institutional effort.

Some key findings include:

  • Rare patients may have antibodies with kappa light chains. This contrasts with current thinking that VITT antibodies can only include lambda light chains. More to come!
  • While VITT anti-PF4 antibodies are clonally restricted, the monoclone/oligoclones are not evident upon study of the entire IgG repertoire, and require anti-PF4 antibody isolation to appreciate clonal restriction. This is in contrast to MGTS where a monoclonal antibody is clearly seen by SPEP/IFE/Mass-Fix.
  • In one patient, we noted persisting platelet activating antibodies 4 yrs after the acute event, with chronic low-grade thrombocytopenia. Long-term follow up may be important in VITT!

Congrats to the entire team!”

Title: Platelet Factor 4 Antibody Persistence and Long-term Pathogenicity in Vaccine-induced Immune Thrombotic Thrombocytopenia

Authors: Adam Kanack, Emily Mauch, Guillaume Roberge, Noah Splinter, Krishna Gundabolu, Geoffrey D. Wool, Gemlyn George, Mouhamed Yazan Abou-Ismail, Kristi J. Smock, David L. Green, Jonathan Coker, Mindy C. Kohlhagen, David L. Murray, Anand Padmanabhan

Read the Full Article on JTH

Anand Padmanabhan

More posts featuring Anand Padmanabhan on Hemostasis Today.